Hybrigenics outlines financial strategy for inecalcitol
This article was originally published in Scrip
Executive Summary
Hybrigenics is dependent on the exercise of warrants that were issued in parallel to its IPO in 2007 to progress its lead product inecalcitol to Phase IIb development, the company's CEO Dr Rémi Delansorne told Scrip.